Navigation Links
Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
Date:10/19/2010

SAN DIEGO, Oct. 19, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that unaudited net product sales for the quarter ended September 30, 2010 were $154.0 million.  Unaudited net product sales for the quarter include $132.4 million for BYETTA® (exanatide) injection and $21.6 million for SYMLIN® (pramlintide acetate) injection.  This compares to net product sales of $192.9 million consisting of $171.1 million for BYETTA and $21.8 million for SYMLIN for the same period in 2009.  Amylin plans to report full financial results for the quarter and nine months ended September 30, 2010 within the next few weeks pending its assessment of the potential financial impact of the U.S. Food and Drug Administration complete response letter regarding BYDUREON™ (exenatide extended-release for injectable suspension).

Amylin also announced that the previously announced quarterly update conference call, originally scheduled for Wednesday, October 20, 2010 at 5:00 p.m. ET/2:00 p.m. PT., has been canceled.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin and Lilly Set Date and Time for Conference Call
2. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
3. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
4. Amylin Pharmaceuticals to Webcast Third Quarter Results
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
7. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
8. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
9. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
10. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
11. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... DIEGO , May 19, 2016 ... (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today ... creating the first cord blood based cancer immunotherapeutic ... provisional patent application, Regen described a generation of ... was potentiated by gene silencing.  The product in ...
(Date:5/18/2016)... ... May 18, 2016 , ... Tech Coast Angels (TCA) ... to Cognition Therapeutics at the annual ACA Summit last week in Philadelphia. ... one of ACA’s member angel groups. It is the highest honor available for an ...
(Date:5/18/2016)... May 18, 2016 The Biotech industry ... not mean that there are no opportunities ahead. Today, ActiveWallSt.com ... (NASDAQ: THLD ), Seattle Genetics Inc. (NASDAQ: ... and Ophthotech Corp. (NASDAQ: OPHT ). Sign up ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s ...
(Date:5/18/2016)... ... May 18, 2016 , ... Every day, ... result of asthma complications.* Costing more than $56 billion in direct costs annually, ... , “For too many, the suffering associated with uncontrolled asthma can be overwhelmingly ...
Breaking Biology Technology:
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):